{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:29:22Z","timestamp":1787498962734,"version":"build-2736575974"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15703-1","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:03:48Z","timestamp":1773446628000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prostate cancer and CAR-T therapy: a systematic review"],"prefix":"10.1186","volume":"26","author":[{"given":"Farigol","family":"Hakem Zadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Bird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"key":"15703_CR1","doi-asserted-by":"publisher","unstructured":"Kratzer TB, Mazzitelli N, Star J, Dahut WL, Jemal A, Siegel RL. Prostate cancer statistics, 2025. CA Cancer J Clin Published Online September. 2025;2. https:\/\/doi.org\/10.3322\/caac.70028.","DOI":"10.3322\/caac.70028"},{"key":"15703_CR2","unstructured":"Spratt DE, Srinivas S, Adra N et al. NCCN Guidelines Index Table of Contents Discussion. Prostate Cancer. Published online 2025."},{"issue":"11","key":"15703_CR3","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","volume":"65","author":"M Kirby","year":"2011","unstructured":"Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180\u201392. https:\/\/doi.org\/10.1111\/j.1742-1241.2011.02799.x.","journal-title":"Int J Clin Pract"},{"issue":"21","key":"15703_CR4","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995\u20132005. https:\/\/doi.org\/10.1056\/NEJMoa1014618.","journal-title":"N Engl J Med"},{"issue":"15","key":"15703_CR5","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or Mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502\u201312. https:\/\/doi.org\/10.1056\/NEJMoa040720.","journal-title":"N Engl J Med"},{"issue":"6suppl","key":"15703_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1200\/jco.2013.31.6_suppl.72","volume":"31","author":"SF Slovin","year":"2013","unstructured":"Slovin SF, Wang X, Hullings M, et al. Chimeric antigen receptor (CAR+) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC). J Clin Oncol. 2013;31(6suppl):72\u201372. https:\/\/doi.org\/10.1200\/jco.2013.31.6_suppl.72.","journal-title":"J Clin Oncol"},{"issue":"33","key":"15703_CR7","doi-asserted-by":"publisher","first-page":"52810","DOI":"10.18632\/oncotarget.10547","volume":"7","author":"JN Graff","year":"2016","unstructured":"Graff JN, Alumkal JJ, Drake CG, et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget. 2016;7(33):52810\u20137. https:\/\/doi.org\/10.18632\/oncotarget.10547.","journal-title":"Oncotarget"},{"issue":"5","key":"15703_CR8","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for Castration-Resistant prostate cancer. N Engl J Med. 2010;363(5):411\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1001294.","journal-title":"N Engl J Med"},{"issue":"3","key":"15703_CR9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17(3):147\u201367. https:\/\/doi.org\/10.1038\/s41571-019-0297-y.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"15703_CR10","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res Off J Am Assoc Cancer Res. 1997;3(1):81\u20135.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"2","key":"15703_CR11","doi-asserted-by":"publisher","first-page":"e1230","DOI":"10.1002\/cl2.1230","volume":"18","author":"NR Haddaway","year":"2022","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis. Campbell Syst Rev. 2022;18(2):e1230. https:\/\/doi.org\/10.1002\/cl2.1230.","journal-title":"Campbell Syst Rev"},{"key":"15703_CR12","unstructured":"Rayyan\u2014a web and mobile app for systematic reviews | Systematic Reviews | Full Text. https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-016-0384-4. Accessed 5 April 2025."},{"issue":"14","key":"15703_CR13","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/pros.23214","volume":"76","author":"RP Junghans","year":"2016","unstructured":"Junghans RP, Ma Q, Rathore R, et al. Phase I trial of Anti-PSMA designer CAR-T cells in prostate cancer: possible role for interacting Interleukin 2-T cell pharmacodynamics as a determinant of clinical response. Prostate. 2016;76(14):1257\u201370. https:\/\/doi.org\/10.1002\/pros.23214.","journal-title":"Prostate"},{"issue":"6suppl","key":"15703_CR14","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1200\/jco.2013.31.6_suppl.216","volume":"31","author":"RP Junghans","year":"2013","unstructured":"Junghans RP. Role for IL2 adjunctive cotherapy for suppression of a solid tumor with designer T cells: phase I trial data in prostate cancer. J Clin Oncol. 2013;31(6suppl):216\u2013216. https:\/\/doi.org\/10.1200\/jco.2013.31.6_suppl.216.","journal-title":"J Clin Oncol"},{"issue":"4","key":"15703_CR15","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan V, Barber-Rotenberg JS, Jung IY, et al. PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2022;28(4):724\u201334. https:\/\/doi.org\/10.1038\/s41591-022-01726-1.","journal-title":"Nat Med"},{"issue":"6suppl","key":"15703_CR16","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1200\/JCO.2022.40.6_suppl.094","volume":"40","author":"M McKean","year":"2022","unstructured":"McKean M, Carabasi MH, Stein MN, et al. Safety and early efficacy results from a phase 1, multicenter trial of PSMA-targeted armored CAR T cells in patients with advanced mCRPC. J Clin Oncol. 2022;40(6suppl):94\u201394. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.094.","journal-title":"J Clin Oncol"},{"key":"15703_CR17","doi-asserted-by":"publisher","unstructured":"Carabasi MH, McKean M, Stein MN, et al. PSMA targeted armored chimeric antigen receptor (CAR) T-cells in patients with advanced mCRPC: A phase I experience. J Clin Oncol Published Online May. 2021;20. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.2534.","DOI":"10.1200\/JCO.2021.39.15_suppl.2534"},{"issue":"6suppl","key":"15703_CR18","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1200\/JCO.2022.40.6_suppl.098","volume":"40","author":"SF Slovin","year":"2022","unstructured":"Slovin SF, Dorff TB, Falchook GS, et al. Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2022;40(6suppl):98\u201398. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.098.","journal-title":"J Clin Oncol"},{"issue":"11","key":"15703_CR19","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen A, Haanen JBAG, Koenecke C, et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med. 2023;29(11):2844\u201353. https:\/\/doi.org\/10.1038\/s41591-023-02612-0.","journal-title":"Nat Med"},{"key":"15703_CR20","doi-asserted-by":"publisher","first-page":"10743","DOI":"10.1038\/s41467-024-53220-6","volume":"15","author":"MN Stein","year":"2024","unstructured":"Stein MN, Dumbrava EE, Teply BA, et al. PSCA-targeted BPX-601 CAR T cells with Pharmacological activation by Rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial. Nat Commun. 2024;15:10743. https:\/\/doi.org\/10.1038\/s41467-024-53220-6.","journal-title":"Nat Commun"},{"issue":"6","key":"15703_CR21","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-024-02979-8","volume":"30","author":"TB Dorff","year":"2024","unstructured":"Dorff TB, Blanchard MS, Adkins LN, et al. PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2024;30(6):1636\u201344. https:\/\/doi.org\/10.1038\/s41591-024-02979-8.","journal-title":"Nat Med"},{"issue":"1","key":"15703_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/pros.20073","volume":"61","author":"Q Ma","year":"2004","unstructured":"Ma Q, Safar M, Holmes E, Wang Y, Boynton AL, Junghans RP. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy. Prostate. 2004;61(1):12\u201325. https:\/\/doi.org\/10.1002\/pros.20073.","journal-title":"Prostate"},{"issue":"3","key":"15703_CR23","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/pros.22749","volume":"74","author":"Q Ma","year":"2014","unstructured":"Ma Q, Gomes EM, Lo ASY, Junghans RP. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy. Prostate. 2014;74(3):286\u201396. https:\/\/doi.org\/10.1002\/pros.22749.","journal-title":"Prostate"},{"issue":"5","key":"15703_CR24","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","volume":"44","author":"JH Esensten","year":"2016","unstructured":"Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA. CD28 costimulation: from mechanism to therapy. Immunity. 2016;44(5):973\u201388. https:\/\/doi.org\/10.1016\/j.immuni.2016.04.020.","journal-title":"Immunity"},{"key":"15703_CR25","unstructured":"Poseida Therapeutics. Inc. A Phase 1 Dose Escalation and Expanded Cohort Study of P-PSMA-101 in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC). clinicaltrials.gov; 2025. https:\/\/clinicaltrials.gov\/study\/NCT04249947.\u00a0 Accessed 17 April 2025."},{"key":"15703_CR26","unstructured":"Shenzhen Geno-Immune Medical Institute. GD2\/PSMA Bi-Specific CAR-T Cells For the Treatment of GD2 and PSMA Positive Solid Tumors. clinicaltrials.gov; 2022. https:\/\/clinicaltrials.gov\/study\/NCT05437315 Accessed 18 April 2025."},{"key":"15703_CR27","unstructured":"Shenzhen Geno-Immune Medical Institute. PSMA\/CD70 Bi-Specific CAR-T Cells for Cancer Treatment. clinicaltrials.gov; 2022. Accessed April 18, 2025. https:\/\/clinicaltrials.gov\/study\/NCT05437341."},{"key":"15703_CR28","doi-asserted-by":"publisher","first-page":"1371345","DOI":"10.3389\/fimmu.2024.1371345","volume":"15","author":"J Philippova","year":"2024","unstructured":"Philippova J, Shevchenko J, Sennikov S. GD2-targeting therapy: a comparative analysis of approaches and promising directions. Front Immunol. 2024;15:1371345. https:\/\/doi.org\/10.3389\/fimmu.2024.1371345.","journal-title":"Front Immunol"},{"key":"15703_CR29","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.3389\/fonc.2020.01000","volume":"10","author":"B Nazha","year":"2020","unstructured":"Nazha B, Inal C, Owonikoko TK. Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy. Front Oncol. 2020;10:1000. https:\/\/doi.org\/10.3389\/fonc.2020.01000.","journal-title":"Front Oncol"},{"key":"15703_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2015.07.007","volume":"155","author":"J Jacobs","year":"2015","unstructured":"Jacobs J, Deschoolmeester V, Zwaenepoel K, et al. CD70: an emerging target in cancer immunotherapy. Pharmacol Ther. 2015;155:1\u201310. https:\/\/doi.org\/10.1016\/j.pharmthera.2015.07.007.","journal-title":"Pharmacol Ther"},{"key":"15703_CR31","unstructured":"Tceleron Therapeutics, Inc. A Phase 1\/2, Open-Label, Multi-Center Study of Dually Armored Chimeric Antigen Receptor (CAR) T-Cells (TmPSMA-02) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC). clinicaltrials.gov; 2023. https:\/\/clinicaltrials.gov\/study\/NCT05489991.\u00a0Accessed 18 April 2025."},{"key":"15703_CR32","unstructured":"University of Pennsylvania. Phase I, Open-Label Study of Dually Armored Chimeric Antigen Receptor (CAR) T Cells (TmPSMA-02) in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC). clinicaltrials.gov. 2024. https:\/\/clinicaltrials.gov\/study\/NCT06046040.\u00a0Accessed 18 April 2025."},{"issue":"6suppl","key":"15703_CR33","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1200\/JCO.2022.40.6_suppl.158","volume":"40","author":"D Barrett","year":"2022","unstructured":"Barrett D, Chagin K, Fountaine TJ, et al. TmPSMA-02: A CD2 endodomain containing double armored PSMA CAR T with enhanced efficacy and lower immune toxicity. J Clin Oncol. 2022;40(6suppl):158\u2013158. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.158.","journal-title":"J Clin Oncol"},{"issue":"9","key":"15703_CR34","doi-asserted-by":"publisher","first-page":"582","DOI":"10.6004\/jnccn.2024.0057","volume":"22","author":"JA Thompson","year":"2024","unstructured":"Thompson JA, Schneider BJ, Brahmer J, et al. NCCN Guidelines\u00ae insights: management of Immunotherapy-Related Toxicities, version 2.2024. J Natl Compr Cancer Netw JNCCN. 2024;22(9):582\u201392. https:\/\/doi.org\/10.6004\/jnccn.2024.0057.","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"15703_CR35","unstructured":"The Affiliated Hospital of Xuzhou Medical University. Clinical Study of PSMA-Targeted CAR-T Cells in the Treatment of Castration-Resistant Prostate Cancer. clinicaltrials.gov. 2022. https:\/\/clinicaltrials.gov\/study\/NCT05354375. Accessed 18 April 2025."},{"key":"15703_CR36","unstructured":"Fang W. Clinical Trial for the Safety and Efficacy of Non-Viral PD1 Integrated Anti-PSMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory Castrate-Resistant Prostate Cancer. clinicaltrials.gov; 2023. https:\/\/clinicaltrials.gov\/study\/NCT04768608. Accessed 18 April 2025."},{"key":"15703_CR37","unstructured":"Shancheng R. The Safety and Efficacy Evaluation of Enhanced Autologous PSMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory Castration Resistant Prostate Cancer. clinicaltrials.gov; 2024. https:\/\/clinicaltrials.gov\/study\/NCT06228404. Accessed 18 April 2025."},{"key":"15703_CR38","unstructured":"Bioray Laboratories. A Phase I Study to Evaluate the Safety and Efficacy of PSMA-CART Co-Expressing LIGHT in Treating Patients With Castrate-Resistant Prostate Cancer (CRPC). clinicaltrials.gov; 2024. https:\/\/clinicaltrials.gov\/study\/NCT04053062. Accessed 18 April 2025."},{"key":"15703_CR39","unstructured":"AvenCell EGH, Multicenter, Open-Label A, Design Phase I. Trial With Genetically Modified T-Cells Carrying Universal Chimeric Antigen Receptors (UniCAR02-T) in Combination With PSMA Peptide Target Module (TMpPSMA) for the Treatment of Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker. clinicaltrials.gov; 2024. https:\/\/clinicaltrials.gov\/study\/NCT04633148. Accessed 18 April 2025."},{"key":"15703_CR40","unstructured":"Chang LJ. Phase I\/II Clinical Trial of 4SCAR-PSMA T Cell Therapy Targeting PSMA Positive Malignancies. clinicaltrials.gov; 2020. https:\/\/clinicaltrials.gov\/study\/NCT04429451. Accessed 18 April 2025."},{"key":"15703_CR41","unstructured":"A Phase 1b Study Evaluating Combinations With PSCA-Targeting Chimeric Antigen Receptor (CAR)-T Cells for Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer. Published online March 24, 2023. https:\/\/clinicaltrials.gov\/study\/NCT05805371. Accessed 19 Jul 2025."},{"key":"15703_CR42","unstructured":"City of Hope Medical Center. A Phase I Study to Evaluate PSCA-Targeting Chimeric Antigen Receptor (CAR)-T Cells for Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer. clinicaltrials.gov; 2025. https:\/\/clinicaltrials.gov\/study\/NCT03873805. Accessed 17 April 2025."},{"key":"15703_CR43","unstructured":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd. PD-1 Silent PSMA\/PSCA Targeted CAR-T for the Treatment of Prostate Cancer. clinicaltrials.gov; 2023. https:\/\/clinicaltrials.gov\/study\/NCT05732948. Accessed 18 April 2025."},{"key":"15703_CR44","doi-asserted-by":"publisher","first-page":"111339","DOI":"10.1016\/j.biopha.2021.111339","volume":"137","author":"JE Zhou","year":"2021","unstructured":"Zhou JE, Yu J, Wang Y, et al. ShRNA-mediated Silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft. Biomed Pharmacother Biomedecine Pharmacother. 2021;137:111339. https:\/\/doi.org\/10.1016\/j.biopha.2021.111339.","journal-title":"Biomed Pharmacother Biomedecine Pharmacother"},{"issue":"6476","key":"15703_CR45","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1126\/science.aay5967","volume":"367","author":"K Reinhard","year":"2020","unstructured":"Reinhard K, Rengstl B, Oehm P, et al. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science. 2020;367(6476):446\u201353. https:\/\/doi.org\/10.1126\/science.aay5967.","journal-title":"Science"},{"key":"15703_CR46","unstructured":"The Second Hospital of Shandong University. Clinical Study on the Safety and Efficacy of CAR-T\/CAR-NK Cells in the Treatment of Recurrent Refractory or Unresectable Solid Tumors. clinicaltrials.gov; 2024. https:\/\/clinicaltrials.gov\/study\/NCT06572956. Accessed 18 April 2025."},{"key":"15703_CR47","unstructured":"AstraZeneca. A Phase I\/II Open Label Study to Evaluate the Safety, Cellular Kinetics, and Efficacy of AZD0754, a Chimeric Antigen Receptor (CAR) T-Cell Therapy Directed Against STEAP2, in Adult Participants With Metastatic Prostate Cancer: APOLLO. clinicaltrials.gov; 2025. https:\/\/clinicaltrials.gov\/study\/NCT06267729. Accessed 18 April 2025."},{"issue":"3","key":"15703_CR48","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s10555-020-09898-3","volume":"39","author":"O Gires","year":"2020","unstructured":"Gires O, Pan M, Schinke H, Canis M, Baeuerle PA. Expression and function of epithelial cell adhesion molecule epcam: where are we after 40 years? Cancer Metastasis Rev. 2020;39(3):969\u201387. https:\/\/doi.org\/10.1007\/s10555-020-09898-3.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"15703_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12865-014-0064-x","volume":"16","author":"Z Deng","year":"2015","unstructured":"Deng Z, Wu Y, Ma W, Zhang S, Zhang YQ. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM. BMC Immunol. 2015;16(1):1. https:\/\/doi.org\/10.1186\/s12865-014-0064-x.","journal-title":"BMC Immunol"},{"key":"15703_CR50","unstructured":"First Affiliated Hospital of Chengdu Medical College. A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer. clinicaltrials.gov. 2017. https:\/\/clinicaltrials.gov\/study\/NCT03013712. Accessed 18 April 2025."},{"key":"15703_CR51","doi-asserted-by":"publisher","first-page":"701006","DOI":"10.3389\/fimmu.2021.701006","volume":"12","author":"WT Zhou","year":"2021","unstructured":"Zhou WT, Jin WL. B7-H3\/CD276: an emerging cancer immunotherapy. Front Immunol. 2021;12:701006. https:\/\/doi.org\/10.3389\/fimmu.2021.701006.","journal-title":"Front Immunol"},{"key":"15703_CR52","unstructured":"PersonGen BT. (Suzhou) Co., Ltd. CD276 CAR-T for Patients With Advanced CD276\u2009+\u2009Solid Tumors. clinicaltrials.gov; 2020. https:\/\/clinicaltrials.gov\/study\/NCT04691713. Accessed 18 April 2025."},{"key":"15703_CR53","doi-asserted-by":"publisher","first-page":"1553987","DOI":"10.3389\/fchem.2025.1553987","volume":"13","author":"DS Jairajpuri","year":"2025","unstructured":"Jairajpuri DS, Hussain A, Alajmi MF, Mohammad T, Shamsi A, Hassan MI. Structure-based identification of bioactive phytochemicals targeting kallikrein-related peptidase 2 for prostate cancer therapy. Front Chem. 2025;13:1553987. https:\/\/doi.org\/10.3389\/fchem.2025.1553987.","journal-title":"Front Chem"},{"key":"15703_CR54","unstructured":"Development LLCA. Phase 1, Dose Escalation Study of JNJ-75229414, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against KLK2 for Metastatic Castration-Resistant Prostate Cancer. clinicaltrials.gov; 2025. https:\/\/clinicaltrials.gov\/study\/NCT05022849. Accessed 18 April 2025."},{"issue":"1","key":"15703_CR55","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3390\/ijms21010336","volume":"21","author":"KL Chen","year":"2020","unstructured":"Chen KL, Li D, Lu TX, Chang SW. Structural characterization of the CD44 stem region for standard and Cancer-Associated isoforms. Int J Mol Sci. 2020;21(1):336. https:\/\/doi.org\/10.3390\/ijms21010336.","journal-title":"Int J Mol Sci"},{"key":"15703_CR56","unstructured":"Chang LJ. Multi-Center Phase I\/II Clinical Trial of 4SCAR-CD44v6 T Cells for Treating Cancer. clinicaltrials.gov; 2020. https:\/\/clinicaltrials.gov\/study\/NCT04427449. Accessed 18 April 2025."},{"key":"15703_CR57","doi-asserted-by":"publisher","first-page":"1562188","DOI":"10.3389\/fimmu.2025.1562188","volume":"16","author":"J Lv","year":"2025","unstructured":"Lv J, Liu Z, Ren X, Song S, Zhang Y, Wang Y. \u03b3\u03b4T cells, a key subset of T cell for cancer immunotherapy. Front Immunol. 2025;16:1562188. https:\/\/doi.org\/10.3389\/fimmu.2025.1562188.","journal-title":"Front Immunol"},{"key":"15703_CR58","doi-asserted-by":"publisher","first-page":"1282758","DOI":"10.3389\/fimmu.2023.1282758","volume":"14","author":"CQ Wang","year":"2023","unstructured":"Wang CQ, Lim PY, Tan AHM. Gamma\/delta T cells as cellular vehicles for anti-tumor immunity. Front Immunol. 2023;14:1282758. https:\/\/doi.org\/10.3389\/fimmu.2023.1282758.","journal-title":"Front Immunol"},{"issue":"15","key":"15703_CR59","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1158\/1078-0432.CCR-23-3495","volume":"30","author":"P Thomas","year":"2024","unstructured":"Thomas P, Paris P, Pecqueur C. Arming V\u03b42 T cells with chimeric antigen receptors to combat cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2024;30(15):3105\u201316. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3495.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"18","key":"15703_CR60","doi-asserted-by":"publisher","first-page":"eadf0108","DOI":"10.1126\/sciadv.adf0108","volume":"9","author":"JS Frieling","year":"2023","unstructured":"Frieling JS, Tordesillas L, Bustos XE, et al. \u03b3\u03b4-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer. Sci Adv. 2023;9(18):eadf0108. https:\/\/doi.org\/10.1126\/sciadv.adf0108.","journal-title":"Sci Adv"},{"key":"15703_CR61","unstructured":"CytoMed Therapeutics Pte Ltd. A Phase I Dose-Escalation Trial to Evaluate Haploidentical \/ Allogeneic Natural Killer Group 2D Ligand (NKG2DL)-Targeting Chimeric Antigen Receptor-Grafted Gamma Delta (\u0393\u03b4) T Cells (CTM-N2D) in Subjects With Relapsed or Refractory Solid Tumour. clinicaltrials.gov; 2019. https:\/\/clinicaltrials.gov\/study\/NCT04107142. Accessed 12 April 2025."},{"issue":"2","key":"15703_CR62","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1209096.","journal-title":"N Engl J Med"},{"key":"15703_CR63","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000088787.95124.4b","author":"KHANMA CARDUCCI","year":"2003","unstructured":"CARDUCCI KHANMA. The evolving role of docetaxel in the management of androgen independent prostate cancer. J Urol Published Online November. 2003. https:\/\/doi.org\/10.1097\/01.ju.0000088787.95124.4b.","journal-title":"J Urol Published Online November"},{"key":"15703_CR64","unstructured":"Gahvari Z. CAR T-Cell Therapy for Solid Tumors: Leveraging Lessons From Hematologic Malignancies. 2025;26. https:\/\/www.onclive.com\/view\/car-t-cell-therapy-for-solid-tumors-leveraging-lessons-from-hematologic-malignancies. Accessed 15 May 2025."},{"key":"15703_CR65","unstructured":"EpCAM-targeting. CAR-T cell immunotherapy is safe and efficacious for epithelial tumors | Science Advances. https:\/\/www.science.org\/doi\/10.1126\/sciadv.adg9721. Accessed 15 May 2025."},{"key":"15703_CR66","doi-asserted-by":"publisher","first-page":"175628722095140","DOI":"10.1177\/1756287220951404","volume":"12","author":"S Handa","year":"2020","unstructured":"Handa S, Hans B, Goel S, Bashorun HO, Dovey Z, Tewari A. Immunotherapy in prostate cancer: current state and future perspectives. Ther Adv Urol. 2020;12:1756287220951404. https:\/\/doi.org\/10.1177\/1756287220951404.","journal-title":"Ther Adv Urol"},{"issue":"12","key":"15703_CR67","doi-asserted-by":"publisher","first-page":"3966","DOI":"10.1158\/1078-0432.CCR-08-0356","volume":"14","author":"A Wallace","year":"2008","unstructured":"Wallace A, Kapoor V, Sun J, et al. Transforming growth factor-beta receptor Blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14(12):3966\u201374. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0356.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"4","key":"15703_CR68","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69. https:\/\/doi.org\/10.1038\/s41408-021-00459-7.","journal-title":"Blood Cancer J"},{"issue":"4","key":"15703_CR69","first-page":"318","volume":"9","author":"B Thompson-Elliott","year":"2021","unstructured":"Thompson-Elliott B, Johnson R, Khan SA. Alterations in TGF\u03b2 signaling during prostate cancer progression. Am J Clin Exp Urol. 2021;9(4):318\u201328.","journal-title":"Am J Clin Exp Urol"},{"issue":"7","key":"15703_CR70","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","volume":"26","author":"CC Kloss","year":"2018","unstructured":"Kloss CC, Lee J, Zhang A, et al. Dominant-Negative TGF-\u03b2 receptor enhances PSMA-Targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol Ther J Am Soc Gene Ther. 2018;26(7):1855\u201366. https:\/\/doi.org\/10.1016\/j.ymthe.2018.05.003.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"issue":"5","key":"15703_CR71","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.eururo.2017.12.008","volume":"73","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Helfand BT, Carneiro BA, et al. Efficacy against human prostate cancer by prostate-specific membrane Antigen-specific, transforming growth Factor-\u03b2 insensitive genetically targeted CD8\u2009+\u2009T-cells derived from patients with metastatic Castrate-resistant disease. Eur Urol. 2018;73(5):648\u201352. https:\/\/doi.org\/10.1016\/j.eururo.2017.12.008.","journal-title":"Eur Urol"},{"issue":"10","key":"15703_CR72","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer EM, Srinivas S, Adra N, et al. Prostate Cancer, version 4.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN. 2023;21(10):1067\u201396. https:\/\/doi.org\/10.6004\/jnccn.2023.0050.","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"15703_CR73","unstructured":"City of Hope Medical Center. A Phase 1b Study Evaluating Combinations With PSCA-Targeting Chimeric Antigen Receptor (CAR)-T Cells for Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer. clinicaltrials.gov; 2024. https:\/\/clinicaltrials.gov\/study\/NCT05805371.\u00a0 Accessed 18 April 2025."},{"issue":"2","key":"15703_CR74","doi-asserted-by":"publisher","first-page":"e1380764","DOI":"10.1080\/2162402X.2017.1380764","volume":"7","author":"SJ Priceman","year":"2018","unstructured":"Priceman SJ, Gerdts EA, Tilakawardane D, et al. Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. Oncoimmunology. 2018;7(2):e1380764. https:\/\/doi.org\/10.1080\/2162402X.2017.1380764.","journal-title":"Oncoimmunology"},{"issue":"6","key":"15703_CR75","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1016\/j.jaci.2020.11.023","volume":"147","author":"R Castillo-Gonz\u00e1lez","year":"2021","unstructured":"Castillo-Gonz\u00e1lez R, Cibrian D, S\u00e1nchez-Madrid F. Dissecting the complexity of \u03b3\u03b4 T-cell subsets in skin homeostasis, inflammation, and malignancy. J Allergy Clin Immunol. 2021;147(6):2030\u201342. https:\/\/doi.org\/10.1016\/j.jaci.2020.11.023.","journal-title":"J Allergy Clin Immunol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15703-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15703-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15703-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:55:47Z","timestamp":1776905747000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15703-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15703"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15703-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]},"assertion":[{"value":"24 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"514"}}